Investor Presentaiton slide image

Investor Presentaiton

Investor presentation ADA 2019 Slide 16 The SOUL trial will provide robust evidence on the cardiovascular benefits of oral semaglutide in people with type 2 diabetes Randomised: 9,642 patients with type 2 diabetes SOUL trial design Oral semaglutide 14 mg + standard of care Placebo + standard of care Event-driven SOUL trial key inclusion criteria Key endpoints Primary: · Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (MACE) Secondary confirmatory: 5-component composite CKD endpoints Cardiovascular Death à composite peripheral artery endpoint Standard of care allows all glucose lowering drugs except GLP-1s; CKD: chronic kidney disease People with type 2 diabetes from 34 countries with primarily moderate Chronic Kidney Disease • HbA1c ≤10% Age ≥50 years At least 1 of the following: Coronary heart disease, Cerebrovascular disease, Symptomatic peripheral arterial disease, Chronic kidney disease Trial initiation: Q2 2019 novo nordisk
View entire presentation